These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 27546726)
1. Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy. Godar M; Morello V; Sadi A; Hultberg A; De Jonge N; Basilico C; Hanssens V; Saunders M; Lambrecht BN; El Khattabi M; de Haard H; Michieli P; Blanchetot C Sci Rep; 2016 Aug; 6():31621. PubMed ID: 27546726 [TBL] [Abstract][Full Text] [Related]
2. A Biparatopic Antibody That Modulates MET Trafficking Exhibits Enhanced Efficacy Compared with Parental Antibodies in MET-Driven Tumor Models. DaSilva JO; Yang K; Perez Bay AE; Andreev J; Ngoi P; Pyles E; Franklin MC; Dudgeon D; Rafique A; Dore A; Delfino FJ; Potocky TB; Babb R; Chen G; MacDonald D; Olson WC; Thurston G; Daly C Clin Cancer Res; 2020 Mar; 26(6):1408-1419. PubMed ID: 31848185 [TBL] [Abstract][Full Text] [Related]
3. A novel bispecific c-MET/CTLA-4 antibody targetting lung cancer stem cell-like cells with therapeutic potential in human non-small-cell lung cancer. Li JF; Niu YY; Xing YL; Liu F Biosci Rep; 2019 May; 39(5):. PubMed ID: 29187584 [TBL] [Abstract][Full Text] [Related]
4. A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors. Gonzalez A; Broussas M; Beau-Larvor C; Haeuw JF; Boute N; Robert A; Champion T; Beck A; Bailly C; Corvaïa N; Goetsch L Int J Cancer; 2016 Oct; 139(8):1851-63. PubMed ID: 27144973 [TBL] [Abstract][Full Text] [Related]
5. MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM. Casaletto JB; Geddie ML; Abu-Yousif AO; Masson K; Fulgham A; Boudot A; Maiwald T; Kearns JD; Kohli N; Su S; Razlog M; Raue A; Kalra A; Håkansson M; Logan DT; Welin M; Chattopadhyay S; Harms BD; Nielsen UB; Schoeberl B; Lugovskoy AA; MacBeath G Proc Natl Acad Sci U S A; 2019 Apr; 116(15):7533-7542. PubMed ID: 30898885 [TBL] [Abstract][Full Text] [Related]
6. Expeditious Generation of Biparatopic Common Light Chain Antibodies Bogen JP; Carrara SC; Fiebig D; Grzeschik J; Hock B; Kolmar H Front Immunol; 2020; 11():606878. PubMed ID: 33424853 [TBL] [Abstract][Full Text] [Related]
7. Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody. Zheng S; Moores S; Jarantow S; Pardinas J; Chiu M; Zhou H; Wang W MAbs; 2016; 8(3):551-61. PubMed ID: 26761634 [TBL] [Abstract][Full Text] [Related]
8. A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors. Yoon A; Lee S; Lee S; Lim S; Park YY; Song E; Kim DS; Kim K; Lim Y Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32143496 [TBL] [Abstract][Full Text] [Related]
9. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics. Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309 [TBL] [Abstract][Full Text] [Related]
10. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987 [TBL] [Abstract][Full Text] [Related]
11. Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Xiong C; Mao Y; Wu T; Kang N; Zhao M; Di R; Li X; Ji X; Liu Y Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257416 [TBL] [Abstract][Full Text] [Related]
12. A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer. Sun ZJ; Wu Y; Hou WH; Wang YX; Yuan QY; Wang HJ; Yu M Oncotarget; 2017 Apr; 8(17):29067-29079. PubMed ID: 28404966 [TBL] [Abstract][Full Text] [Related]
14. DuoHexaBody-CD37 Oostindie SC; van der Horst HJ; Kil LP; Strumane K; Overdijk MB; van den Brink EN; van den Brakel JHN; Rademaker HJ; van Kessel B; van den Noort J; Chamuleau MED; Mutis T; Lindorfer MA; Taylor RP; Schuurman J; Parren PWHI; Beurskens FJ; Breij ECW Blood Cancer J; 2020 Apr; 10(3):30. PubMed ID: 32341336 [TBL] [Abstract][Full Text] [Related]
15. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA MAbs; 2015; 7(3):584-604. PubMed ID: 25875246 [TBL] [Abstract][Full Text] [Related]
16. Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule. Kelton C; Wesolowski JS; Soloviev M; Schweickhardt R; Fischer D; Kurosawa E; McKenna SD; Gross AW Arch Biochem Biophys; 2012 Oct; 526(2):219-25. PubMed ID: 22426455 [TBL] [Abstract][Full Text] [Related]
17. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity. Choi HJ; Kim YJ; Lee S; Kim YS Mol Cancer Ther; 2013 Dec; 12(12):2748-59. PubMed ID: 24132142 [TBL] [Abstract][Full Text] [Related]
18. Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain. Dimasi N; Fleming R; Sachsenmeier KF; Bezabeh B; Hay C; Wu J; Sult E; Rajan S; Zhuang L; Cariuk P; Buchanan A; Bowen MA; Wu H; Gao C MAbs; 2017 Apr; 9(3):438-454. PubMed ID: 28055299 [TBL] [Abstract][Full Text] [Related]
19. Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. Dong J; Sereno A; Snyder WB; Miller BR; Tamraz S; Doern A; Favis M; Wu X; Tran H; Langley E; Joseph I; Boccia A; Kelly R; Wortham K; Wang Q; Berquist L; Huang F; Gao SX; Zhang Y; Lugovskoy A; Martin S; Gouvis H; Berkowitz S; Chiang G; Reff M; Glaser SM; Hariharan K; Demarest SJ J Biol Chem; 2011 Feb; 286(6):4703-17. PubMed ID: 21123183 [TBL] [Abstract][Full Text] [Related]
20. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies. Shen J; Vil MD; Jimenez X; Zhang H; Iacolina M; Mangalampalli V; Balderes P; Ludwig DL; Zhu Z J Immunol Methods; 2007 Jan; 318(1-2):65-74. PubMed ID: 17126853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]